ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Alterity Therapeutics Limited (ATHE) stock surged +2.94%, trading at $3.50 on NASDAQ, up from the previous close of $3.40. The stock opened at $3.43, fluctuating between $3.31 and $3.50 in the recent session.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Employees | 10 |
Beta | 0.7 |
Sales or Revenue | $4.02M |
5Y Sales Change% | 3.276% |
Fiscal Year Ends | June |
Sector | Healthcare |
Industry | Biotechnology |